OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by Two Sigma Investments LP

Two Sigma Investments LP increased its holdings in OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 136.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,647,567 shares of the biotechnology company's stock after buying an additional 949,671 shares during the quarter. Two Sigma Investments LP owned about 0.24% of OPKO Health worth $2,422,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Cibc World Markets Corp purchased a new stake in OPKO Health during the fourth quarter worth $45,000. Zacks Investment Management acquired a new position in shares of OPKO Health in the fourth quarter worth about $49,000. Ieq Capital LLC purchased a new stake in shares of OPKO Health during the 4th quarter worth about $52,000. Mercer Global Advisors Inc. ADV grew its position in shares of OPKO Health by 105.6% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 43,167 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 22,167 shares during the period. Finally, Catalyst Funds Management Pty Ltd purchased a new position in shares of OPKO Health in the 4th quarter valued at about $91,000. Institutional investors and hedge funds own 64.63% of the company's stock.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 200,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $1.74 per share, with a total value of $348,000.00. Following the completion of the acquisition, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. This trade represents a 0.09% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders acquired 700,000 shares of company stock worth $1,123,000 over the last three months. Insiders own 49.69% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on OPK. Barrington Research reiterated an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research report on Thursday, May 1st. Wall Street Zen downgraded OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. HC Wainwright reissued a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. Finally, JPMorgan Chase & Co. started coverage on shares of OPKO Health in a research report on Friday, April 25th. They set a "neutral" rating for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $2.75.

OPKO Health Price Performance

Shares of OPKO Health stock traded down $0.04 during mid-day trading on Wednesday, reaching $1.35. 1,628,431 shares of the stock traded hands, compared to its average volume of 3,845,977. The stock has a market capitalization of $1.07 billion, a PE ratio of -7.08 and a beta of 1.42. The business has a 50-day moving average of $1.39 and a 200 day moving average of $1.54. OPKO Health, Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $2.04. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. During the same period in the prior year, the company posted ($0.12) earnings per share. The firm's revenue for the quarter was down 13.7% compared to the same quarter last year. On average, analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.